Skip to main content
OpenTrials
Completed

NCT Number: NCT02425969

A Trial in Stable Intermediate Coronary Lesions and Grey-zone FFR Values

In this randomised controlled trial of patients with stable angina and documented intermediate coronary disease with indeterminate or "grey-zone" Fractional Flow Reserve (FFR) we will randomise patients to either optimal medical therapy alone versus optimal medical therapy with PCI and they will be followed up for the primary endpoint of anginal control as measured by the Seattle Angina Questionnaire at 3 months.

Completed

Looking for future studies?

Notify Me

Key information

Age range

18 year–90 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Golden Jubilee National Hospital

Glasgow, Dunbartonshire, G81 4DY, United Kingdom

About this study

Pressure derived fractional flow reserve (FFR) is recognised as being the gold standard method of assessing the physiological significance of angiographically intermediate lesions. A grey-zone exists between the originally validated cut-off for ischemia of <0.75 and the conventionally adopted cut- off of ≤0.80. Pilot data from our centre has suggested that only 1 in 3 coronary arteries with grey-zone FFR values demonstrate myocardial perfusion defects on stress cardiac MRI and others have suggested that the clinical outcomes in patients with grey-zone FFR are favorable with medical therapy alone. As such, stenting all lesions with grey-zone FFR (as currently recommended) may represent over-treatment and could attenuate the overall benefit of an FFR strategy. In addition to this there are flow derived resistance indices of stenosis severity that have superior diagnostic accuracy and may be helpful in correctly classifying patients with grey-zone FFR. In this study we will a comprehensive analysis of lesions with grey-zone FFR values (0.75-0.82 inclusive) using invasive hyperemic pressure, flow and resistance derived indices of severity with quantitative and qualitative 3T perfusion MRI to enable identification of the best invasive predictors of true perfusion defects on 3T cardiac MRI. Patients will be randomised to optimal medical therapy alone versus optimal medical therapy with PCI and followed up for the primary endpoint of anginal control as measured by the Seattle Angina Questionnaire at 3 months.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Patients >18 years
  • 30-80% Diameter Stenosis on QCA
  • Stable angina
  • Non ST-elevation myocardial infarction (NSTEMI) with stable symptoms
  • Able to provide informed consent

Exclusion criteria

  • STEMI within 5 days
  • Tortuous vessels which would render pressure wire studies difficult or impossible
  • Heavily calcified vessels which would render pressure wire studies difficult or impossible
  • Unstable symptoms requiring definitive interventional management
  • Severe claustrophobia
  • Age >90 years
  • Life expectancy <1 year
  • Estimated Glomerular Filtration Rate <30 mls/min/1.73m2
  • Inability to undergo MRI scanning due to metallic implant or incompatible permanent pacemaker
  • Severe asthma or inability to safely receive an adenosine infusion
  • Left mainstem disease ≤50% or if considered clinically significant by the operating cardiologist either on angiography or intravascular ultrasound.

Treatment and study plan

PCI

Procedure

Patients will have balloon angioplasty and coronary stent insertion for their grey-zone FFR lesion.

Optimal medical therapy

Drug

Optimal Medical therapy consists of secondary prevention which will include high dose statin and aspirin as well as anti-anginal therapy according to ESC 2013 international treatment guidelines for stable angina as follows; B-Blocker or Calcium channel blocker as first line agents and Nicorandil or Nitrates or Ranolazine as second line treatment titrated against symptoms to maximum tolerated dose. ACE inhibitors or Angiotensin Receptor Blockers will be prescribed if patients also have a diagnosis of hypertension, LVEF ≤40%, diabetes or CKD where appropriate.

Primary outcomes

  1. Angina status as per Seattle Angina Questionnaire

    Time frame: 3 months

    Anginal severity as measured by the Seattle Angina Score at 3 months compared with baseline in patients randomized to PCI versus medical therapy.

Secondary outcomes

  1. MACE

    Time frame: 3 and 12 months

    MACE (Death, myocardial infarction, urgent revascularisation and stroke) in patients randomized to PCI versus medical therapy.

  2. Myocardial infarction

    Time frame: 3 and 12 months

    Myocardial infarction in patients randomized to PCI versus medical therapy.

  3. Urgent Revascularisation

    Time frame: 3 and 12 months

    Urgent Revascularisation of the grey-zone FFR lesion in patients randomized to PCI versus medical therapy.

  4. Total number of anti-anginal medications

    Time frame: 3 and 12 months

    Total number of anti-anginal medications in patients randomized to PCI versus medical therapy.

Sponsors and collaborators

Lead sponsor

Golden Jubilee National Hospital

Other Gov

Collaborators

  • British Heart Foundation
  • University of Glasgow

Registry information

Official study title

A Randomised Controlled Trial in Stable Intermediate Coronary Lesions and Grey-zone FFR Values With Evaluation of the Diagnostic Utility of Invasive Coronary Physiological Indices and Quantitative Perfusion MRI. The GzFFR Study

Acronym: GzFFR

Important dates

Study start
2015
Primary completion
2016
Study completion
2016
First posted
Apr 24, 2015
Registry last updated
Mar 3, 2017

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.